Philip Scheltens (Edmond Sadaka/Sipa via AP Images)
January 14, 2021 11:04 AM EST
Financing

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

Nicole DeFeudis

Editor

Big Phar­ma has re­treat­ed from neu­ro­science over the past sev­er­al years, aban­don­ing or trim­ming back pro­grams af­ter fac­ing set­backs in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times